-
公开(公告)号：WO2012081850A2
公开(公告)日：2012-06-21
申请号：PCT/KR2011/009298
申请日：2011-12-02
CPC classification number: A61L31/16 , A61F2/82 , A61F2240/001 , A61F2250/0067 , A61F2310/00407 , A61L27/54 , A61L31/022 , A61L31/088 , A61L2300/22 , A61L2300/236 , A61L2300/252 , A61L2300/256 , A61L2300/258 , A61L2300/41 , A61L2300/416 , A61L2300/418 , A61L2300/45 , A61L2300/802 , A61L2400/18 , A61L2420/08
Abstract: 본발명은 티타늄 산화물 박막코팅을 이용한 유전자 전달 스텐트 및 그 제조방법에 관한 것으로，상기 본 발명에 따른 스텐트는 항염증 및 항혈전 작용이 있는 약물의 탑재와 동시에 혈관 평활근 세포의 증식을 억제할 수 있는 유전자의 전달을 동시에 가능하게 함으로써 후기 혈전증이나 금속 과민증을 감소시킬 수 있을 뿐만 아니라 스텐트 내 혈관 재협착을 방지할 수 있어 혈관 삽입용 스텐트의치료효과를 증대시킬 수 있는 장점이 있다.
Abstract translation: 本发明涉及使用氧化钛薄膜包衣的基因递送支架，以及制造基因递送支架的方法。 基因递送支架装载有具有抗炎和抗血栓形成功能的药物，并且提供用于抑制血管平滑肌细胞生长的基因。 因此，可以降低晚期血栓形成或金属变态反应，并且可以防止支架区域中的血管再狭窄，从而在插入血管时增加基因递送支架的治疗效果。
-
公开(公告)号：KR1020120114501A
公开(公告)日：2012-10-17
申请号：KR1020110032046
申请日：2011-04-07
Applicant: 전남대학교병원
IPC: A61K31/165 , A61K31/16 , A61P9/10 , A61P9/00
Abstract: PURPOSE: A composition for restenosia prevention and a medicine for arteriosclerosis including the same are provided to prevent restenosia inside a stent and to minimize a side effect in which tunica intima of the blood vessel endothelial cell is slowly re-progressed after the stent treatment. CONSTITUTION: A composition for restenosia prevention includes trichostatin A(TSA) represented as chemical formula 1. The active ingredient prevents the formation of vascularization tunica intima or suppression of vascular smooth muscle cells. The composition is coated on the stent or balloon and is injected in the artery part and orally or non-orally administered. The composition is directly spread on the artery part in 1-3 mm thickness and is injected. The artery part is atherosclerosis panel site. The medicine for arteriosclerosis includes the composition for preventing restenosis. The medicine is a stent in which the composition is spread on the surface.
Abstract translation: 目的：提供一种用于预防再狭窄的组合物和包括其的用于动脉硬化的药物以防止支架内的再狭窄，并且使支架治疗后血管内皮细胞的内膜缓慢地再次进行的副作用最小化。 构成：预防复发的组合物包括以化学式1表示的曲古抑菌素A（TSA）。活性成分可防止内膜血管形成或血管平滑肌细胞的抑制。 将组合物涂布在支架或球囊上，并注入动脉部分，口服或非口服给药。 将组合物直接铺展在1-3mm厚度的动脉部分上并注射。 动脉部分为动脉粥样硬化斑块。 用于动脉硬化的药物包括用于预防再狭窄的组合物。 药物是组合物在表面上扩散的支架。
-
公开(公告)号：KR101116673B1
公开(公告)日：2012-02-22
申请号：KR1020110121949
申请日：2011-11-22
Applicant: 전남대학교병원
CPC classification number: A61L31/16 , A61F2/82 , A61F2240/001 , A61F2250/0067 , A61F2310/00407 , A61L27/54 , A61L31/022 , A61L31/088 , A61L2300/22 , A61L2300/236 , A61L2300/252 , A61L2300/256 , A61L2300/258 , A61L2300/41 , A61L2300/416 , A61L2300/418 , A61L2300/45 , A61L2300/802 , A61L2400/18 , A61L2420/08
Abstract: PURPOSE: A gene-releasing stent using titanium-oxide is provided to reduce latter thrombosis or metal anaphylaxis, and to prevent the vascular restenosis inside a stent. CONSTITUTION: A manufacturing method of a gene-releasing stent using titanium-oxide comprises: a step of coating oxidation titanium which is TiO2-xNx (0.001
Abstract translation: 目的：提供使用氧化钛的基因释放支架，以减少后期血栓形成或金属过敏反应，并防止支架内的血管再狭窄。 构成：使用氧化钛的基因释放支架的制造方法包括：在金属支架的表面上涂覆TiO 2-x N x（0.001 <= x <= 1）的氧化钛的步骤; 改性涂层氧化钛表面并引入羟基的步骤; 通过将羟基与药物的官能团结合形成药物层的步骤，并且将药物附着在氧化钛层的顶部; 以及通过将寡核苷酸与药物组合形成寡核苷酸相互连接的步骤，并将寡核苷酸连接在药物层的顶部。
-
-
Search Results
3
records
(took 0.016 seconds)
